Soliris Market 2026: Beyond the 5.5% CAGR Journey and Key Growth Drivers

Ryan Lee

— 11 min read
Share

The Soliris (eculizumab) market has matured into one of the most strategically complex segments in the rare disease and complement inhibitor therapy landscape. From a baseline of approximately USD 4.1 billion in 2020, the market has expanded to an estimated USD 5.1 billion in 2025, reflecting sustained demand growth across multiple approved indications. The forward trajectory points to a compound annual growth rate of 5.5 percent through 2032, with the total addressable market projected to reach roughly USD 7.2 billion by the end of the forecast period. This expansion is not a simple continuation of historical momentum. It is being reshaped by biosimilar entry, evolving regulatory frameworks, indication expansions, and shifting reimbursement dynamics. For executives, investors, and procurement leaders, the market presents a dual narrative: enduring volume growth in established indications, and structural disruption that will redefine pricing power, market access, and competitive positioning over the next several years.

Market Landscape and Core Challenges

The current market structure reflects a highly concentrated ecosystem with limited supplier diversity. Concentration metrics indicate that the top three players account for approximately 98 percent of total market share, while the top five entities maintain a similar share of around 98.5 percent. This level of consolidation points to an environment where a small number of organizations control manufacturing, commercialization, and access pathways. Such concentration has historically supported pricing stability and predictable supply, but it also amplifies vulnerability to regulatory shifts, manufacturing disruptions, and the strategic decisions of a handful of decision-makers.

Demand continues to be anchored by two primary clinical applications: paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). These indications have driven consistent utilization growth, supported by long-term clinical evidence and deepening physician familiarity with complement inhibition. At the same time, expanded indications in generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD) have broadened the patient base and increased the strategic value of the molecule beyond its original orphan disease roots. The treatment modalities split between plasma exchange and plasma infusion further illustrates the operational complexity of the market, with each pathway carrying distinct logistics, cost profiles, and patient management considerations.

Key Challenges and Inflection Points

The market is navigating several structural pressures that will determine competitive outcomes over the next five years. First, biosimilar entry is beginning to alter the pricing and access architecture. The approval and commercialization of EPYSQLI (eculizumab-aagh) in the United States introduces a direct therapeutic alternative and sets the stage for price negotiation, formulary competition, and potential shifts in prescribing behavior. The timing, scale, and execution of biosimilar uptake will be a defining variable for market margins and volume distribution.

Second, exclusivity timelines are creating near-term inflection points. The expiration of exclusivity for the NMOSD indication in mid-2026 is a notable event that could accelerate competitive pressure and reshape access negotiations in that segment. Even where exclusivity remains intact, the presence of an approved biosimilar changes the strategic calculus for originators, payers, and providers. The market is no longer operating under a single-source assumption, and that shift affects forecasting, contract design, and launch planning.

Third, regulatory and safety management requirements continue to shape operational complexity. The ongoing REMS program for Soliris and Ultomiris, including recent modifications tied to pediatric indications, adds a layer of compliance and process management that affects adoption, site-of-care readiness, and patient support infrastructure. These requirements can slow initiation in certain settings and increase the importance of education, coordination, and support services in durable market access.

Fourth, reimbursement and patient cost dynamics remain a critical variable. Support mechanisms such as copay assistance programs help address infusion-related cost burdens, but they also highlight the underlying pressure on affordability and access. As payers scrutinize value, outcomes, and total cost of care, the market will increasingly reward strategies that demonstrate durable clinical benefit, efficient administration, and clear economic rationale.

Key Drivers Shaping Market Dynamics

The market’s growth and transformation are being propelled by interconnected forces across innovation, regulation, demand behavior, and supply chain and cost structures. Understanding how these drivers interact is essential for anticipating where value will be created and where disruption may emerge.

Technological and Clinical Innovation

The molecule’s clinical footprint has expanded well beyond its initial rare disease applications. Recent regulatory actions have extended approved use to pediatric populations in gMG, reflecting a broader trajectory of indication expansion and patient segment diversification. Alongside these approvals, the presentation of long-term safety and efficacy data in NMOSD and gMG reinforces the therapeutic narrative and supports confidence in sustained use. Data spanning multiple years of postmarketing surveillance, including analyses from Japan, provides reassurance on durability and supports the case for continued utilization where clinically appropriate.

These innovation signals matter because they influence both demand and competitive positioning. Expanded indications create new patient pools and increase the strategic relevance of the therapy across neurology and hematology. At the same time, long-term evidence helps defend against substitution pressure by reinforcing differentiated clinical value. In a market where biosimilars are entering, the originator’s ability to sustain a compelling clinical narrative and real-world evidence base becomes a central part of preservation strategy.

Policy and Regulatory Environment

Regulatory developments are shaping both the pace and the nature of market change. Recent updates include FDA approvals for pediatric gMG indications, product monograph adjustments in Canada, and modifications to safety management programs tied to pediatric use. These actions illustrate a regulatory environment that is both enabling expansion and reinforcing oversight where clinical complexity is high. The presence of a REMS program, with periodic modifications, signals that access will continue to be governed by structured safety protocols, which can affect adoption speed, site readiness, and the administrative burden for providers and patients.

For commercial strategy, the regulatory trajectory suggests that timing and compliance capability will be differentiators. Companies that can integrate new indication pathways efficiently, maintain robust safety and monitoring processes, and align with evolving regional requirements will be better positioned to capture demand as it materializes. At the same time, regulatory milestones such as exclusivity changes can create windows of opportunity for competitors and should be treated as strategic triggers rather than passive calendar events.

Demand-Side Shifts

Demand behavior is evolving as the patient population broadens and as clinical practice patterns mature. The growth of PNH and aHUS utilization reflects sustained confidence in complement inhibition, while the emergence of gMG and NMOSD adoption indicates that physicians and care teams are increasingly integrating the therapy into broader treatment algorithms. This expansion is not uniform across all settings. Adoption depends on diagnostic capabilities, specialist awareness, infrastructure for infusion or exchange therapies, and the availability of patient support services.

Patient and provider preferences are also being influenced by access considerations. Copay assistance and other support mechanisms play a role in reducing out-of-pocket barriers, particularly for infusion-based therapies where total cost of care can be significant. Over time, demand will increasingly reflect a balance between clinical fit and economic accessibility. Providers and patients are likely to favor options that combine proven outcomes with manageable logistics and predictable costs. That dynamic creates room for competitive differentiation not only on efficacy but also on service design, site-of-care flexibility, and administrative ease.

Supply Chain and Cost Structure Dynamics

Manufacturing and supply arrangements are becoming more strategically visible as biosimilar entry redistributes responsibilities across development, production, and commercialization. In the biosimilar pathway, one organization may handle development, regulatory registration, manufacture, and supply, while a partner manages U.S. marketing and sales. This division of responsibilities reflects a broader trend toward specialized execution and partnership-based market entry. For the originator, the manufacturing footprint, including site licensing and production continuity, remains a core element of supply assurance and regulatory standing.

Cost structures are being reshaped by multiple forces. Biosimilar competition introduces price pressure that can affect net realization, even where list pricing remains stable. At the same time, the complexity of infusion and exchange therapies creates inherent cost drivers related to administration, monitoring, and support. The interaction between product cost, administration cost, and reimbursement design will influence which segments remain most profitable and which require more aggressive access strategies. Procurement organizations and manufacturers alike will need to map total cost rather than focus on unit price alone.

Competitive Landscape and Leading Strategies

The competitive environment is defined by a concentrated originator ecosystem, an emerging biosimilar pathway, and the strategic role of parent and partner organizations. The market remains heavily weighted toward a single originator that discovered and commercialized the molecule, supported by the parent company’s broader portfolio oversight and global reach. That structure has enabled consistent commercialization, long-term evidence generation, and access program development. However, it also concentrates strategic dependence, making the market sensitive to a small number of corporate and regulatory decisions.

Samsung Bioepis and Teva together represent a notable competitive development. Samsung Bioepis has taken responsibility for the development, regulatory registration, manufacture, and supply of the approved biosimilar for U.S. commercialization, while Teva leads U.S. marketing and sales following a strategic partnership. This arrangement highlights a modern market entry model in which manufacturing and regulatory expertise are paired with commercial execution capability. The biosimilar launch introduces a direct alternative and is expected to influence formulary dynamics, pricing negotiations, and potentially prescribing patterns over time. The partnership structure also suggests that the biosimilar pathway is not solely a pricing story; execution quality, supply reliability, and commercial reach will determine how effectively competition translates into market share movement.

Strategic Positioning and Differentiation

The originator’s positioning has historically rested on several pillars: first-in-class status, depth of clinical evidence, broad indication coverage, and established access support infrastructure. These assets provide a strong foundation but do not automatically insulate against biosimilar competition. Preservation strategy will likely depend on strengthening the clinical narrative, expanding real-world evidence, and maintaining robust patient and provider support. Indication expansions, such as the pediatric gMG approval, can help sustain relevance across diverse patient segments and demonstrate continued innovation.

The biosimilar entrant’s differentiation is likely to center on access appeal, execution reliability, and the ability to offer a comparable therapeutic option with competitive commercial terms. Success will depend on more than availability; it will require effective education, dependable supply, and a commercial engine capable of navigating specialty access channels. The partnership model may provide an advantage by combining development and manufacturing depth with dedicated U.S. commercial responsibility, but execution risk remains significant in a market where provider familiarity and safety management requirements are high.

Market Structure Evolution

The market is likely to evolve through a combination of differentiation and incremental competition rather than abrupt fragmentation. Because concentration remains so high, the early phase of biosimilar competition may involve negotiated access, selective adoption, and careful provider engagement rather than broad displacement. Over time, the dynamics could shift toward more explicit price competition and formulary positioning, especially where payers demand optionality or where cost pressures intensify. The expiration of exclusivity for the NMOSD indication is a catalyst that could accelerate this trajectory in one segment, while the broader market may continue to be shaped by indication-specific demand and evidence profiles.

A key structural trend is the increasing importance of partnership and specialized execution. Whether in originator expansion or biosimilar entry, organizations are relying on focused capabilities across development, manufacturing, regulatory registration, and commercialization. This specialization can improve efficiency and market readiness, but it also raises coordination challenges. The organizations that manage these interdependencies well will be better positioned to scale, maintain supply continuity, and respond to access and regulatory changes.
IVIG Market

Looking ahead three to five years, several trends are likely to shape the market’s direction and create distinct commercial opportunities. These trends are interconnected, and the most successful participants will be those who can align product strategy, access strategy, and operational execution around them.

Trend 1: Gradual but Decisive Biosimilar Impact

The biosimilar entry in the United States is likely to unfold as a gradual but increasingly meaningful force rather than an immediate disruption. Early adoption may be shaped by formulary decisions, provider comfort, supply confidence, and payer incentives. Over time, however, the presence of an approved alternative will influence pricing expectations and access negotiations. The commercial opportunity here lies in managing the transition proactively. For originators, this means reinforcing differentiated value, strengthening patient retention mechanisms, and preparing access strategies that can respond to comparative positioning. For biosimilar entrants, the opportunity is to build credibility through dependable supply, clear clinical comparability, and effective commercial execution, particularly in specialty channels where trust and logistics matter.

A related risk is that biosimilar impact may be uneven across indications and regions. In segments with strong clinical loyalty or complex management requirements, displacement may be slower. In segments where payers push for optionality or where cost pressure is acute, adoption may advance more quickly. Forecasting should therefore be indication-sensitive and regionally differentiated rather than assuming a uniform shift.
PW Consulting

Trend 2: Indication Expansion and Portfolio Value Growth

Continued indication expansion represents a durable growth lever. Recent pediatric approvals and long-term data presentations support a widening clinical footprint across gMG and related neurology applications, while PNH and aHUS remain foundational demand anchors. The opportunity is to integrate these indications into coordinated access and evidence strategies that maximize diagnosed patient capture and reinforce treatment continuity. Indication growth also creates the potential to deepen the therapeutic narrative, which can be valuable in defending share and supporting pricing discussions.

The risk is that expansion increases operational and compliance complexity. Each new segment can introduce different diagnostic pathways, provider audiences, safety management requirements, and reimbursement environments. Organizations need to ensure that commercial infrastructure, patient support, and regulatory processes can scale with the expanded footprint without diluting service quality or access reliability.

Trend 3: Access, Pricing, and Total Cost Realignment

As competition and cost scrutiny intensify, the market will likely shift toward more explicit attention to total cost of care, including administration, monitoring, and support costs. Access programs, copay support, and site-of-care considerations will become more central to commercial outcomes. The opportunity is to design value propositions that address not only the therapy itself but also the surrounding cost and logistics burden. For providers and payers, this may mean favoring options that reduce administrative friction or improve predictability. For manufacturers and partners, it creates room to differentiate through service design, patient support, and access facilitation.

The uncertainty here lies in how reimbursement environments evolve. Payer behavior, regional policy differences, and the timing of exclusivity changes will influence how quickly and in what form price and access realignment occurs. Organizations should prepare for multiple scenarios rather than rely on a single assumed path.
Worldwide Belimumab Market

Strategic Recommendations for Decision-Makers

The Soliris market is entering a phase where strategy matters as much as clinical heritage. The following recommendations are oriented toward the different roles that interact with this market, with emphasis on actionable priorities rather than broad observations.

For Manufacturers and Commercial Leaders

Prioritize evidence continuity and differentiated service as core defense mechanisms. In a market with biosimilar entry and near-term exclusivity changes, maintaining confidence in clinical value and real-world performance is essential. Align indication expansion with robust communication, provider education, and patient support so that growth in one segment does not create strain in another. Also, treat supply and regulatory readiness as strategic assets. Manufacturing continuity, licensing compliance, and safety program execution are not back-office concerns; they are direct enablers of market access and trust.

For Investors and Strategic Allocators

Focus on the interaction between biosimilar execution and segment-level demand rather than on headline market size alone. The commercial outcome will depend on how effectively competitors convert regulatory approval into reliable supply, credible messaging, and formulary presence. Pay attention to exclusivity timelines, indication-specific adoption patterns, and the relative strength of access infrastructure, since these variables will shape cash flow durability and competitive displacement risk. The market’s concentration also means that a small number of strategic moves can have outsized effects, so monitoring partnership structures and launch execution is critical.

For Procurement and Access Stakeholders

Evaluate total value across product, administration, support, and continuity rather than unit cost in isolation. In infusion- and exchange-intensive therapies, operational reliability and patient support can be as important as price. As biosimilar options become available, assess comparability, supply assurance, and the practical implications for site readiness and patient management. Access negotiations should account for the possibility of gradual competitive effects, with contract designs that preserve flexibility as the market evolves.

Across all roles, the most valuable capability will be timely, granular intelligence. Market concentration, biosimilar timing, exclusivity events, indication expansion, and access dynamics are moving together, and the implications vary by segment and region. Organizations that can anticipate these shifts and translate them into concrete operational decisions will be better positioned to protect margins, capture demand, and manage risk. For decision-makers seeking deeper segmentation, regional detail, and customized scenario planning, a full research report can provide the additional granularity needed to move from strategic direction to execution-ready planning.

For detailed analysis of this topic, please visit the official page: Soliris (Eculizumab) Market

Lacy Lee
Senior Marketing Manager
sales@pmarketresearch.com
00852-95632430
PW Consulting: www.pmarketresearch.com

Read more